Novo Nordisk Launches Bidding War With Pfizer for Metsera Acquisition

The logo of Danish pharmaceutical company Novo Nordisk at their headquarters in Bagsvaerd, Denmark, on Feb. 1, 2017. Liselotte Sabroe/Scanpix Denmark/AFP via Getty ImagesNovo Nordisk, the Denmark-based Ozempic creator, has launched a bidding war with Pfizer Inc. to acquire New York-based Metsera Inc.Founded in 2022, Metsera is a clinical-stage biopharmaceutical firm specializing in treatments for obesity and metabolic diseases.